Spectral Medical (STU:SD4) Moat Score: 3/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:SD4 Spectral Medical Inc STU:SD4
14 GF Score
Price €0.83
GF Value €0.56
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Spectral Medical Moat Score?

Spectral Medical STU:SD4 +1.23% 14 Moat Score is 3 as of Jul. 15, 2026. GuruFocus rates STU:SD4 with a GF Score™ of 14/100 and a GF Value™ of €0.56 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Spectral Medical ranks better than 76.74% on this metric.

Spectral Medical has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Spectral Medical has No Moat: Spectral Medical Inc has limited market share and lacks strong intellectual property. The medical device industry is competitive with low customer switching costs and minimal brand loyalty. The company does not demonstrate significant regulatory barriers or cost advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Spectral Medical might have No Moat - Very weak/transient advantages.

Spectral Medical  (STU:SD4) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Spectral Medical Moat Score Related Terms

STU:SD4 vs TMO, DHR, IDXX: Moat Score Comparison

For the Diagnostics & Research subindustry, Spectral Medical's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spectral Medical Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's Moat Score distribution charts can be found below:

* The bar in red indicates where Spectral Medical's Moat Score falls into.


STU:SD4
14GF Score
Spectral Medical Inc STU:SD4
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Spectral Medical (STU:SD4) has a Moat Score of 3 as of Jul. 15, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Spectral Medical ranks #50 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 23.3%.
Is Spectral Medical's Moat Score too high?
Spectral Medical's current Moat Score is 3. Based on the distribution chart, Spectral Medical ranks #50 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Spectral Medical has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's Moat Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #50 out of 215 companies for Moat Score. This places Spectral Medical in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Spectral Medical's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (STU:SD4) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.56, compared to a current price of €0.83 — trading 47.3% above its estimated fair value. The current Moat Score is 3. Spectral Medical's overall GF Score™ is 14/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Spectral Medical (STU:SD4), the current Moat Score is 3 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spectral Medical (STU:SD4) Overvalued in 2026?

Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued. The current stock price of €0.83 is trading 47.3% above its estimated GF Value™ of €0.56. GuruFocus considers Spectral Medical to be Significantly Overvalued.

Key valuation signals for STU:SD4:

  • Moat Score: 3
  • GF Value™: €0.56 vs. price of €0.83 (47.3% above fair value)
  • GF Score™: 14/100 with 9 warning signs

No single metric tells the full story. See the STU:SD4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spectral Medical Business Description

Other Exchanges EDTXF:USAEDT:Canada
Address 135 The West Mall, Unit 2, Finance, Toronto, ON, CAN, M9C 1C2
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
14GF Score

Get the complete analysis for STU:SD4

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.83
Price
€0.56
GF Value